Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.54 |
| ▸ | CNR2 | P34972 | 12/20 | 0.46 |
| ▸ | CNR1 | P21554 | 8/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144410 | 0.99 | CTSK (0.55) | CTSKCNR2CNR1CTSSSMN1; SMN2 | |
| SCHEMBL7340009 | 0.86 | CTSK (0.56) | CTSKCTSSSMN1; SMN2 | |
| SCHEMBL7340018 | 0.86 | CTSK (0.56) | CTSKCTSSSMN1; SMN2 | |
| SCHEMBL13293247 | 0.80 | CTSK (0.45) | CTSK | |
| SCHEMBL8823956 | 0.79 | CTSK (0.53) | CTSKCTSSSMN1; SMN2 | |
| SCHEMBL8823957 | 0.78 | CTSK (0.55) | CTSKCTSSSMN1; SMN2 | |
| SCHEMBL11977974 | 0.78 | CTSK (0.47) | CTSK | |
| SCHEMBL4134832 | 0.78 | CNR2 (0.43) | CNR2CNR1SMN1; SMN2 | |
| SCHEMBL7769892 | 0.77 | PPID (0.42) | CTSKCNR1 | |
| SCHEMBL7883345 | 0.77 | SMN1; SMN2 (0.45) | CTSKCNR2CTSSSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940785-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SmithKline Beecham Corporation (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007030761-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | CTSK 3473/4885CNR2 57/4885CNR1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.